PE20231661A1 - Derivados de acido ursolico sinteticos y metodos de uso de los mismos - Google Patents
Derivados de acido ursolico sinteticos y metodos de uso de los mismosInfo
- Publication number
- PE20231661A1 PE20231661A1 PE2023002112A PE2023002112A PE20231661A1 PE 20231661 A1 PE20231661 A1 PE 20231661A1 PE 2023002112 A PE2023002112 A PE 2023002112A PE 2023002112 A PE2023002112 A PE 2023002112A PE 20231661 A1 PE20231661 A1 PE 20231661A1
- Authority
- PE
- Peru
- Prior art keywords
- bond
- synthetic
- methods
- acid derivatives
- ursolic acid
- Prior art date
Links
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Abstract
REFERIDO A LOS COMPUESTOS DE FORMULA (I-A) EN DONDE: EL ENLACE ENTRE EL ATOMO 1 Y EL ATOMO 2 ES UN ENLACE SENCILLO, UN ENLACE DOBLE O UN ENLACE DOBLE EPOXIDADO; X 2 ES UN ENLACE SIMPLE O UN ENLACE DOBLE; N ES 0-6; X 2 ES OXO, O X 2 SE TOMA JUNTO CON Y COMO SE DEFINE A CONTINUACION, SIEMPRE QUE CUANDO X 2 SEA OXO, ENTONCES EL ENLACE ENTRE EL ATOMO 12 Y X 2 SEA UN DOBLE ENLACE, Y CUANDO X 2 SE TOME JUNTO CON Y COMO SE DEFINE A CONTINUACION, QUE EL ENLACE ENTRE EL ATOMO 12 Y X2 ES UN ENLACE SENCILLO; R2 ES HIDROGENO O HIDROXI.TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163199694P | 2021-01-18 | 2021-01-18 | |
| PCT/US2022/012831 WO2022155614A1 (en) | 2021-01-18 | 2022-01-18 | Synthetic ursolic acid derivatives and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231661A1 true PE20231661A1 (es) | 2023-10-17 |
Family
ID=80222334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002112A PE20231661A1 (es) | 2021-01-18 | 2022-01-18 | Derivados de acido ursolico sinteticos y metodos de uso de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240140986A1 (es) |
| EP (1) | EP4277916A1 (es) |
| JP (1) | JP2024504637A (es) |
| KR (1) | KR20230147077A (es) |
| CN (1) | CN117015548A (es) |
| AU (1) | AU2022208727A1 (es) |
| CA (1) | CA3204434A1 (es) |
| CL (1) | CL2023002064A1 (es) |
| CO (1) | CO2023010422A2 (es) |
| IL (1) | IL304530A (es) |
| MX (1) | MX2023008454A (es) |
| PE (1) | PE20231661A1 (es) |
| TW (1) | TW202245795A (es) |
| WO (1) | WO2022155614A1 (es) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200942231A (en) | 2008-01-11 | 2009-10-16 | Reata Pharmaceuticals Inc | Synthetic triterpenoids and methods of use in the treatment of disease |
| TW201004627A (en) * | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| CN104250280A (zh) * | 2008-04-18 | 2014-12-31 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物 |
| NZ588710A (en) | 2008-04-18 | 2012-12-21 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| WO2009129545A1 (en) * | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| LT2683731T (lt) | 2011-03-11 | 2019-07-10 | Reata Pharmaceuticals, Inc. | C4-monometiltriterpenoido dariniai ir jų panaudojimo būdai |
| RS61544B1 (sr) | 2012-04-27 | 2021-04-29 | Reata Pharmaceuticals Inc | Derivat 2,2-difluoropropionamida metil bardoksolona, njegove farmaceutske supstance i polimorfi za upotrebu za lečenje izvesnih stanja |
| WO2013188818A1 (en) * | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| BR112015005200B1 (pt) | 2012-09-10 | 2022-07-05 | Reata Pharmaceuticals, Inc | Composto derivado de c17-heteroaril de ácido oleanólico, composição farmacêutica compreendendo o referido composto e uso do mesmo |
| TWI630212B (zh) * | 2012-09-10 | 2018-07-21 | 瑞塔醫藥有限責任公司 | 丁香油素（ｏｌｅａｎｏｌｉｃ ａｃｉｄ）之ｃ１７－烷二基與烯二基衍生物及其使用方法 |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| UY35534A (es) * | 2013-04-24 | 2014-10-31 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
| CN108290922B (zh) * | 2015-09-23 | 2021-12-07 | 里亚塔医药公司 | 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 |
| EP3538104A1 (en) * | 2016-11-08 | 2019-09-18 | Reata Pharmaceuticals, Inc. | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
| WO2020068689A1 (en) * | 2018-09-28 | 2020-04-02 | Fronthera U.S. Pharmaceuticals Llc | Terpinoid derivatives and uses thereof |
-
2022
- 2022-01-18 US US18/261,732 patent/US20240140986A1/en active Pending
- 2022-01-18 AU AU2022208727A patent/AU2022208727A1/en active Pending
- 2022-01-18 WO PCT/US2022/012831 patent/WO2022155614A1/en active Application Filing
- 2022-01-18 JP JP2023542885A patent/JP2024504637A/ja active Pending
- 2022-01-18 PE PE2023002112A patent/PE20231661A1/es unknown
- 2022-01-18 MX MX2023008454A patent/MX2023008454A/es unknown
- 2022-01-18 CA CA3204434A patent/CA3204434A1/en active Pending
- 2022-01-18 EP EP22703206.7A patent/EP4277916A1/en active Pending
- 2022-01-18 TW TW111102086A patent/TW202245795A/zh unknown
- 2022-01-18 KR KR1020237028003A patent/KR20230147077A/ko unknown
- 2022-01-18 CN CN202280019965.8A patent/CN117015548A/zh active Pending
-
2023
- 2023-07-14 CL CL2023002064A patent/CL2023002064A1/es unknown
- 2023-07-17 IL IL304530A patent/IL304530A/en unknown
- 2023-08-09 CO CONC2023/0010422A patent/CO2023010422A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504637A (ja) | 2024-02-01 |
| MX2023008454A (es) | 2023-08-07 |
| EP4277916A1 (en) | 2023-11-22 |
| CN117015548A (zh) | 2023-11-07 |
| TW202245795A (zh) | 2022-12-01 |
| AU2022208727A1 (en) | 2023-08-03 |
| CL2023002064A1 (es) | 2023-12-29 |
| CA3204434A1 (en) | 2022-07-21 |
| KR20230147077A (ko) | 2023-10-20 |
| IL304530A (en) | 2023-09-01 |
| CO2023010422A2 (es) | 2023-08-28 |
| US20240140986A1 (en) | 2024-05-02 |
| WO2022155614A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5700772A2 (es) | Composiciones de pirazole utiles como inhibidores de gsk-3 | |
| BR112014008261A2 (pt) | composições de tratamento de lavatório autoadesivas | |
| PE20191043A1 (es) | Composicion farmaceutica | |
| MY192703A (en) | Compositions containing tucaresol or its analogs | |
| AR045234A1 (es) | Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen. | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR065963A1 (es) | Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso | |
| ECSP055575A (es) | Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel. | |
| AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
| PH12021550049A1 (en) | Selective estrogen receptor degraders. | |
| BR112012013049A2 (pt) | potencializador do efeito antitumor. | |
| CL2019002220A1 (es) | Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos. | |
| CR20220482A (es) | Ácido sulfúrico modificado y sus usos | |
| CO2018010787A2 (es) | Compuesto de griseofulvina | |
| AR115698A1 (es) | Tieniloxazolonas y análogos de las mismas | |
| PE20191044A1 (es) | Composicion farmaceutica | |
| CL2018001407A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| MX2018001735A (es) | Compuestos espirocíclicos de fumagillol y compuestos bicíclicos fusionados y métodos de elaboración y uso de los mismos. | |
| CL2018003110A1 (es) | Preparación y dispersión de formulaciones de emulsión estable. | |
| UY36541A (es) | “proceso para la fabricación de una solución de un hidrógenocarbonato alcalinotérreo”. | |
| PE20140890A1 (es) | Derivados de isoxazolidina | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| PE20231661A1 (es) | Derivados de acido ursolico sinteticos y metodos de uso de los mismos | |
| AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
| TR201909029T4 (tr) | Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler. |